Aurinia Pharmaceuticals Inc. (AUPH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 99.89M USD | Liabilities, Current |
| Cash and equivalents | 179.73M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | 45.15M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $99.89M | $179.73M | (m) | (m) | $45.15M | (m) |
| 2026-03-31 | (m) | $86.56M | $40.75M | (m) | (m) | $46.41M | (m) |
| 2025-12-31 | (m) | $93.72M | $80.16M | (m) | (m) | $45.69M | (m) |
| 2025-09-30 | (m) | $76.22M | $72.89M | (m) | (m) | $44.79M | (m) |
| 2025-06-30 | (m) | $78.27M | $52.91M | (m) | (m) | $46.50M | (m) |
| 2025-03-31 | (m) | $68.41M | $66.11M | (m) | (m) | $46.20M | (m) |
| 2024-12-31 | (m) | $97.76M | $83.40M | (m) | (m) | $39.23M | (m) |
| 2024-09-30 | (m) | $78.61M | $36.63M | (m) | (m) | $38.71M | (m) |
| 2024-06-30 | (m) | $76.90M | $33.27M | (m) | (m) | $38.85M | (m) |
| 2024-03-31 | (m) | $71.05M | $63.91M | (m) | (m) | $39.76M | (m) |
| 2023-12-31 | (m) | $77.19M | $48.76M | (m) | (m) | $39.70M | (m) |
| 2023-09-30 | (m) | $73.89M | $45.56M | (m) | (m) | $32.82M | (m) |
| 2023-06-30 | (m) | $61.66M | $81.39M | (m) | (m) | $33.16M | (m) |
| 2023-03-31 | (m) | $42.05M | $88.33M | (m) | (m) | $31.75M | (m) |
| 2022-12-31 | (m) | $46.11M | $94.09M | (m) | (m) | $24.75M | (m) |
| 2022-09-30 | (m) | $41.77M | $85.34M | (m) | (m) | $25.32M | (m) |
| 2022-06-30 | (m) | $34.63M | $151.41M | (m) | (m) | $25.86M | (m) |
| 2022-03-31 | (m) | $33.84M | $131.64M | (m) | (m) | $26.27M | (m) |
| 2021-12-31 | (m) | $40.65M | $231.64M | (m) | (m) | $19.33M | (m) |
| 2021-09-30 | (m) | $37.54M | $57.59M | (m) | (m) | $19.29M | (m) |
| 2021-06-30 | (m) | $29.32M | $121.56M | (m) | (m) | $17.38M | (m) |
| 2021-03-31 | (m) | $21.15M | $156.59M | (m) | (m) | $15.94M | (m) |
| 2020-12-31 | (m) | $32.00M | $272.35M | (m) | (m) | $13.93M | (m) |
| 2019-12-31 | (m) | $11.29M | $306.02M | (m) | (m) | $0.00 | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |